Latest Health News

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Ava Risk Group has suspended its dividend policy to reinvest capital into its growth strategy, signaling a shift in priorities for shareholders. The board will reassess this stance annually.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

Compumedics Limited has reported record sales orders and a return to profitability in FY25, setting the stage for robust growth in FY26 driven by US market traction and SaaS expansion.

Great Dirt Resources has secured a significant exploration licence in the Pilbara lithium province and bolstered its finances with a $335,000 R&D tax rebate, setting the stage for accelerated exploration activities.

Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.

Kingsgate Consolidated’s Chatree Gold Mine delivered a robust quarter with gold production exceeding 20,000 ounces, aligning with its revised FY25 guidance and boosting cash reserves.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Proteomics International’s subsidiary OxiDx has unveiled a pioneering test that detects muscle damage in thoroughbred racehorses, promising to transform recovery management in the racing industry. The test’s commercial launch is slated for the second half of 2025.

Pharmx Technologies has resumed trading on the ASX following the renewal of its pivotal National Diabetes Services Scheme agreement, signaling stability for the healthcare tech firm.

InteliCare has launched a three-month trial of its AI-powered platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy with a leading aged care provider.